查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症领域人工智慧的全球市场（~2030年）：公司类型（整合套件）、应用（药物发现、新药设计、诊断、精准医疗、基因组学）、技术（CNN、NLP）、癌症类型（肺癌）、最终按使用者（医院/製药公司）/地区
市场调查报告书
商品编码
1632129

癌症领域人工智慧的全球市场（~2030年）：公司类型（整合套件）、应用（药物发现、新药设计、诊断、精准医疗、基因组学）、技术（CNN、NLP）、癌症类型（肺癌）、最终按使用者（医院/製药公司）/地区

AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma),& Region-Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 581 Pages | 订单完成后即时交付

价格

肿瘤学人工智慧的市场规模预计将从2024年的24.5亿美元成长到2030年的115.2亿美元，预测期内复合年增长率为29.4%。

市场成长的推动因素包括对具有成本效益的癌症治疗和解决方案的需求不断增长、简化的药物发现流程、医疗记录和患者资料的快速数位化、癌症病例数量的增加以及监管合规要求等。

调查范围
调查年份 2022-2030
基准年 2023年
预测期 2024-2030
考虑单位 金额（美元）
按细分市场 按公司类型、应用程式、癌症类型、技术、部署模型和最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

本报告调查了肿瘤领域的全球人工智慧市场，并提供了市场概况、市场成长的各种影响因素分析、技术和专利趋势、法律制度、案例研究、市场规模趋势和预测以及各种其他信息它总结了按细分市场和地区、竞争环境以及主要企业概况进行的详细分析。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 生态系分析
  • 案例研究分析
  • 价值链分析
  • 波特五力分析
  • 监管状况
  • 专利分析
  • 技术分析
  • 产业动态
  • 价格分析
  • 2025年重大会议和活动
  • 主要相关利益者和采购标准
  • 影响客户业务的趋势/干扰
  • 最终用户分析
  • 投资金筹措场景
  • 生成式人工智慧对肿瘤市场人工智慧的影响

第六章 癌症领域的人工智慧市场：依技术分类

  • 机器学习
    • 深度学习
    • 监督学习
    • 强化学习
    • 无监督学习
    • 其他的
  • 自然语言处理（NLP）
  • 上下文感知处理和计算
  • 电脑视觉
  • 影像分析

第七章 癌症领域人工智慧市场：依应用分类

  • 药物发现
    • 目标识别/检验
    • HIT 识别/优先级
    • HIT 到潜在客户识别/潜在客户生成
    • 先导药物最适化
    • 候选人选择/检验
  • 药物开发
    • 临床前测试
    • 人体试验的预测模型
    • 临床试验优化
    • 适应性研究设计和监测
  • 诊断/早期发现
    • 影像诊断/放射诊断
    • 数位病理学/组织病理学
    • 液态生物检体/生物标记检测
    • 遗传风险预测
  • 治疗计划/个性化
    • 个人化治疗方案
    • 放射治疗
    • 化疗
    • 免疫疗法
    • 标靶治疗
    • 手术计划/支持
  • 病人参与/远端监控
    • 症状管理/虚拟援助
    • 远端患者监护
    • 病患教育/赋权
  • 治疗后监测/倖存者护理
    • 復发监测
    • 长期结果预测
    • 心理健康支持系统
  • 资料管理/分析
  • 其他的

第八章癌症领域的人工智慧市场：按癌症类型

  • 固态肿瘤
    • 乳癌
    • 肺癌
    • 摄护腺癌
    • 大肠直肠癌
    • 脑肿瘤
    • 其他的
  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
    • 其他的
  • 其他的

第九章癌症领域的人工智慧市场：按最终用户划分

  • 医疗服务提供方
    • 医院/诊所
    • 专业中心
    • 研究所/诊断中心
    • 其他的
  • 製药和生物技术公司
  • 医疗设备/医疗设备製造商
  • 学术/研究机构
  • 政府/监管机构
  • 医疗保险公司
  • 其他的

第10章肿瘤学人工智慧市场：按公司类型

  • 利基/点解决方案供应商
  • 整合套件/平台提供商
  • 技术提供者
  • 业务流程服务供应商

第十一章 癌症领域的人工智慧市场：按实施模式

  • 云端基础模式
  • 本地部署模式
  • 混合模式

第十二章肿瘤学人工智慧市场：按地区

  • 北美洲
    • 宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 宏观经济展望
    • 中国
    • 印度
    • 日本
    • 其他的
  • 拉丁美洲
    • 宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东/非洲
    • 宏观经济展望
    • 海湾合作委员会国家
    • 其他的

第十三章竞争格局

  • 主要参与企业的策略/优势
  • 主要企业收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业
  • 企业评估矩阵：Start-Ups企业/中小企业
  • 企业价值评估及财务指标
  • 品牌/软体比较
  • 竞争场景

第十四章 公司简介

  • 主要企业
    • NVIDIA CORPORATION
    • GE HEALTHCARE
    • SIEMENS HEALTHINEERS AG
    • F. HOFFMANN-LA ROCHE LTD
    • INSILICO MEDICINE
    • CONCERTAI
    • MEDTRONIC
    • ORACLE
    • KONINKLIJKE PHILIPS NV
    • PREDICTIVE ONCOLOGY
    • EXSCIENTIA
    • PATHAI, INC.
    • CUREMETRIX, INC.
    • MINDPEAK GMBH
    • PAIGE AI, INC.
    • TEMPUS AI, INC.
    • IKTOS
  • 其他公司
    • AZRA AI
    • CUREMATCH, INC.
    • ONCOLENS
    • TRIOMICS
    • CLINAKOS
    • PERTHERA, INC.
    • CELLWORKS GROUP, INC.
    • BIOMY, INC.

第十五章附录

Product Code: HIT 9231

The global AI in Oncology market is projected to reach USD 11.52 billion by 2030 from USD 2.45 billion in 2024, at a CAGR of 29.4% from 2024 to 2030. The market's growth is fuelled by the growing demand for cost-effective cancer treatments & solutions, streamlining of the drug discovery process, rapid digitization of healthcare records and patient data, the growing volume of cancer cases, and regulatory compliance requirements.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD)
SegmentsBy Player Type, Application, Cancer Type, Technology, Deployment Model, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

In March 2024, the journal published by the American Cancer Society stated the following key points:

  • More than 80% of AI devices that are FDA-approved are used in cancer detection & diagnosis. These devices have applications in the following: pathology (19.7%), radiology (54.9), and radiation oncology (8.5%).
  • AI aided in decreasing the workload of radiologists in breast cancer screening by 30% and in comparison to healthcare professionals, AI maintained more accuracy.
  • AI combined with human evaluations improved cancer detection rates by 8% in various studies.
  • Precision medicine tools powered by AI contributed to the 33% decline in cancer mortality rates over the past 32 years by enabling better diagnoses, tailored treatments, and optimized clinical decision-making.

However, integration with existing healthcare systems, data privacy, and security constraints pose a significant challenge within this market.

"Machine learning held the largest share in technology type in the AI in oncology market in 2023."

The AI in oncology market is segmented based on technology into machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, and image analysis (including optical character recognition). The machine learning segment held the largest market share in 2023. Further, the machine learning segment includes deep learning (including convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies. Among these, deep learning is the largest segment owing to its capability to analyze and process vast and complex datasets including medical images with improved efficiency. Within deep learning technologies such as CNNs are effective for image-based cancer detection, while RNNs and GANs are used to improve the temporal pattern analysis and data synthesis. Moreover, deep learning's scalability, adaptability and precision in analyzing and identifying the subtle patterns in cancer helped in improving the diagnosis, risk predictions and treatment optimization.

"By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period."

By player type, the AI in oncology market is divided into niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers. The integrated suite/platform providers segment accounts for the largest and is projected to be the fastest-growing segment over the forecast year. "By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period." The growth is attributed to the fact that these providers offer comprehensive end-to-end solutions to streamline workflows across all treatment sectors of cancer such as detection, diagnosis, monitoring, and treatment planning. Such platforms help to integrate technologies including NLP, computer vision, and machine learning resulting in better clinical decision-making and offering seamless data interoperability.

Moreover, integrated suite/platform helps in decreasing the need for multiple vendors as they are unified systems due to their scalability and flexibility which results in cost effective solution. This holistic approach drives adoption and fuels rapid growth.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in Oncology market is segmented mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The AI in oncology market in Asia Pacific is projected to register at the highest CAGR rate during the forecast period. The growth of this region is due to the development of healthcare infrastructure, and government initiatives to modernize and digitalize the healthcare industry particularly due to rising cancer cases, growth in minimally invasive cancer treatments, and to increase in the survival rate of cancer patients. Countries such as Japan, China, and India are focusing on developing cost-effective solutions in cancer care emphasizing the importance of AI-driven data management to handle sensitive patient information and ensure compliance with regulatory mandates for healthcare data standardization. Various key players and startups in the countries are promoting AI use in cancer such as Niramai, a Bangalore-based health tech startup, developed Thermalytix, an AI-driven breast cancer screening solution. The technology uses non-invasive, radiation-free thermal imaging and machine learning algorithms to detect breast cancer at an earlier stage compared to traditional methods. The solution is designed for all ages and ensures privacy, portability, and high accuracy. It is available in over 30 cities across 200+ hospitals in India and is expanding globally to different countries, thereby, transforming preventive cancer care.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
  • By Designation: Directors (35%), Managers (40%), and Others (25%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report

    • Certara USA. (US)
    • Siemens Healthineers (Germany)
    • GE Healthcare (US)
    • ConcertAI (US)
    • Medtronic (Ireland)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Oracle(US)
    • NVIDIA Corporation(US)
    • Koninklijke Philips N.V. (Netherlands)
    • PathAI, Inc. (US)
    • CureMetrix, Inc. (US)
    • Mindpeak GmbH (Germany)
    • Paige AI, Inc. (US)
    • Predictive Oncology (US)
    • Exscientia (UK)
    • Insilico Medicine (US)
    • Iktos (Paris)
    • Tempus (US)
    • Azra AI (US)
    • CureMatch, Inc. (US)
    • OncoLens (US)
    • Triomics (US)
    • Clinakos. (US)
    • Perthera, Inc (US)
    • Cellworks Group, Inc. (US)
    • biomy, Inc. (Japan)

Research Coverage

This research report categorizes the AI in oncology market by player type [niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers], by application [drug discovery {target identification & validation, lead identification & optimization, de novo drug design}, drug development {preclinical testing, predictive modeling for human trials, clinical trial optimization, adaptive trial design & monitoring}, diagnosis & early detection {imaging & radiology (mammography, computed tomography, magnetic resonance imaging (MRI), nuclear imaging (PET & SPECT), X-ray imaging, ultrasound, others), digital pathology & histopathology, liquid biopsy & biomarker detection, genetic risk prediction}, treatment planning & personalization {personalized treatment planning (precision medicine & genomic analysis, radiomics and radiogenomics, predictive models for treatment response, treatment recommendation systems), radiation therapy, chemotherapy, immunotherapy, targeted therapy (combination & dose optimization, AI-guided drug delivery), surgical planning & assistance (preoperative imaging and 3D modeling, intraoperative guidance and robotics, postoperative analysis & recovery)}, patient engagement & remote monitoring {symptom management & virtual assistance, remote patient monitoring, patient education & empowerment}, post-treatment surveillance & survivorship care {recurrence monitoring, long-term outcome prediction, mental health & support systems}, data management & analytics, other applications, by cancer type (solid tumors [including breast cancer lung cancer, prostate cancer, colorectal cancer, brain tumors, and other tumors], hematologic malignancies (including leukemia, lymphoma, multiple myeloma, other hematologic malignancies), by technology [machine learning {deep learning (convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies}, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition)], by deployment [on-premises model, cloud-based model, and hybrid model], by end user [healthcare providers {hospitals & clinics, specialty centers, laboratories & diagnostic centers, others}, pharmaceutical & biotechnology companies, medical device/equipment companies, academic & research institutions, government & regulatory agencies, healthcare payers, and others}, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in oncology market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in oncology market. Competitive analysis of upcoming startups in the AI in oncology market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (supportive regulations, growing necessity to reduce healthcare costs, reduction in costs and improved operational efficiency with AI in oncology platforms, rising demand for streamlined clinical trials, technological advancements in AI algorithms, rising cancer prevalence globally), restraints (ensuring data security is a major concern for both patients and users, elevated costs associated with adoption of AI, resistance to adoption), opportunities (focus on personalized treatment plans, collaborative efforts, AI-driven drug discovery), and challenges (limited availability of datasets, interoperability issues) influencing the growth of the AI in oncology market
  • Solution Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in oncology market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the AI in oncology market across varied regions.
  • Market Diversification: Exhaustive information about new solutions, untapped geographies, recent developments, and investments in the AI in oncology market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US), CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), Exscientia (UK), and Insilico Medicine (US), among others in AI in oncology market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
        • 2.1.2.1.1 Key data from primary sources
        • 2.1.2.1.2 Key industry insights
      • 2.1.2.2 Breakdown of primary interviews
  • 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.3 MARKET SIZE ESTIMATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 MARKET SIZING ASSUMPTIONS
    • 2.5.2 OVERALL STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS AI IN ONCOLOGY MARKET
  • 4.2 AI IN ONCOLOGY MARKET, BY REGION
  • 4.3 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL AND COUNTRY
  • 4.4 AI IN ONCOLOGY MARKET, BY COUNTRY
  • 4.5 AI IN ONCOLOGY MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of cancer disease
      • 5.2.1.2 Growing need for early detection and diagnosis
      • 5.2.1.3 Advancements in precision cancer treatment
      • 5.2.1.4 Support from regulatory authorities
      • 5.2.1.5 Increasing investments and funding
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High initial costs
      • 5.2.2.2 Data integrity and algorithm validation
      • 5.2.2.3 Integration with existing systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Radiomics and imaging analysis
      • 5.2.3.2 Clinical trial optimization
      • 5.2.3.3 Personalized treatment plans
      • 5.2.3.4 Integration of multi-omics data
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited availability of datasets
      • 5.2.4.2 Data privacy and security
  • 5.3 ECOSYSTEM ANALYSIS
  • 5.4 CASE STUDY ANALYSIS
    • 5.4.1 SIEMENS HEALTHINEERS IMPLEMENTED SYNGO.VIA RT IMAGE SUITE POWERED BY NVIDIA GPU-BASED SHERLOCK AI SUPERCOMPUTER
    • 5.4.2 AI IN ONCOLOGY FOR PERSONALIZED TREATMENT PLANNING
    • 5.4.3 PERSONALIZED OUTREACH FOR ONCOLOGISTS WITH TAKEDA'S AI SOLUTION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 BARGAINING POWER OF SUPPLIERS
    • 5.6.2 BARGAINING POWER OF BUYERS
    • 5.6.3 THREAT OF SUBSTITUTES
    • 5.6.4 THREAT OF NEW ENTRANTS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 NORTH AMERICA
    • 5.7.2 EUROPE
    • 5.7.3 ASIA PACIFIC
    • 5.7.4 MIDDLE EAST & AFRICA
    • 5.7.5 LATIN AMERICA
    • 5.7.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR AI IN ONCOLOGY
    • 5.8.2 JURISDICTION ANALYSIS
    • 5.8.3 MAJOR PATENTS IN AI IN ONCOLOGY MARKET
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Machine learning
      • 5.9.1.2 Natural language processing
      • 5.9.1.3 Computer vision
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 High-performance computing
      • 5.9.2.2 Next-generation sequencing
      • 5.9.2.3 Digital twins
      • 5.9.2.4 Real-world evidence/real-world data
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Cloud computing
      • 5.9.3.2 Theranostics
      • 5.9.3.3 Augmented and virtual reality
  • 5.10 INDUSTRY TRENDS
    • 5.10.1 SHIFT TOWARD PERSONALIZED ONCOLOGY
    • 5.10.2 EXPANSION OF AI-BASED CLINICAL TRIALS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE, BY DEPLOYMENT MODEL
    • 5.11.2 AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS, BY REGION (2023)
  • 5.12 KEY CONFERENCES AND EVENTS, 2025
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS
    • 5.13.2 BUYING CRITERIA
  • 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 END USER ANALYSIS
    • 5.15.1 UNMET NEEDS
    • 5.15.2 END USER EXPECTATIONS
  • 5.16 INVESTMENT AND FUNDING SCENARIO
  • 5.17 IMPACT OF GENERATIVE AI ON AI IN ONCOLOGY MARKET
    • 5.17.1 KEY USE CASES
    • 5.17.2 CASE STUDIES OF GENERATIVE AI IMPLEMENTATION
      • 5.17.2.1 Case Study 1: Accelerated drug discovery with Generative AI and streamlined workflows
    • 5.17.3 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.17.3.1 Pharmaceutical research and development market
      • 5.17.3.2 Radiology and medical imaging market
      • 5.17.3.3 Healthcare delivery systems market
    • 5.17.4 USER READINESS AND IMPACT ASSESSMENT
      • 5.17.4.1 User readiness
        • 5.17.4.1.1 Use A: Healthcare providers
        • 5.17.4.1.2 User B: Pharmaceutical & biotechnology companies
      • 5.17.4.2 Impact assessment
        • 5.17.4.2.1 User A: Healthcare providers
        • 5.17.4.2.2 User B: Pharmaceutical & biotechnology companies

6 AI IN ONCOLOGY MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
  • 6.2 MACHINE LEARNING
    • 6.2.1 DEEP LEARNING
      • 6.2.1.1 Need to streamline clinical workflows, reduce delays, and improve patient outcomes to drive market
      • 6.2.1.2 Convolutional neural networks
      • 6.2.1.3 Recurrent neural networks
      • 6.2.1.4 Generative adversarial networks
      • 6.2.1.5 Graph neural networks
      • 6.2.1.6 Others
    • 6.2.2 SUPERVISED LEARNING
      • 6.2.2.1 Surge in demand for accurate predictions and tailored treatments to drive market
    • 6.2.3 REINFORCEMENT LEARNING
      • 6.2.3.1 Extensive use in drug discovery to drive market
    • 6.2.4 UNSUPERVISED LEARNING
      • 6.2.4.1 Ability to perform complex tasks and uncover potential drug candidates to drive market
    • 6.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
  • 6.3 NATURAL LANGUAGE PROCESSING
    • 6.3.1 EMERGING DEVELOPMENTS IN ONCOLOGY CARE TO DRIVE MARKET
  • 6.4 CONTEXT-AWARE PROCESSING AND COMPUTING
    • 6.4.1 ABILITY TO OPTIMIZE CLINICAL WORKFLOWS TO DRIVE MARKET
  • 6.5 COMPUTER VISION
    • 6.5.1 ELEVATED DEMAND FOR PRECISION MEDICINE TO DRIVE MARKET
  • 6.6 IMAGE ANALYSIS
    • 6.6.1 AUTOMATION OF COMPLEX IMAGING TASKS TO DRIVE MARKET

7 AI IN ONCOLOGY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    • 7.2.1 TARGET IDENTIFICATION & VALIDATION
      • 7.2.1.1 Emphasis on avoiding last-stage failure in drug discovery to boost growth
    • 7.2.2 HIT IDENTIFICATION & PRIORITIZATION
      • 7.2.2.1 Need for large-scale data analysis in HTS screening to drive adoption
    • 7.2.3 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
      • 7.2.3.1 AI-driven lead generation to improve selectivity and binding mechanisms
    • 7.2.4 LEAD OPTIMIZATION
      • 7.2.4.1 Need to accelerate make-design-test cycles and high possibility of clinical drug failure to spur market
    • 7.2.5 CANDIDATE SELECTION & VALIDATION
      • 7.2.5.1 Candidate selection and validation to facilitate early drug discovery
  • 7.3 DRUG DEVELOPMENT
    • 7.3.1 PRECLINICAL TESTING
      • 7.3.1.1 Need to identify risks and optimize candidates to boost growth
    • 7.3.2 PREDICTIVE MODELING FOR HUMAN TRIALS
      • 7.3.2.1 Need for leveraging AI for accurate dose selection and safety assessments to boost growth
    • 7.3.3 CLINICAL TRIAL OPTIMIZATION
      • 7.3.3.1 Need to enhance trial efficiency and outcomes with AI-driven insights to propel market
    • 7.3.4 ADAPTIVE TRIAL DESIGN & MONITORING
      • 7.3.4.1 AI-driven adaptive trial design & monitoring help improve flexibility and success rates
  • 7.4 DIAGNOSIS & EARLY DETECTION
    • 7.4.1 IMAGING & RADIOLOGY
      • 7.4.1.1 Mammography
        • 7.4.1.1.1 Need for accurate diagnosis of breast cancer to propel market
      • 7.4.1.2 Computed tomography (CT)
        • 7.4.1.2.1 Need for early diagnosis of solid tumors in lungs, liver, and brain to drive growth
      • 7.4.1.3 Magnetic resonance imaging (MRI)
        • 7.4.1.3.1 Need for optimizing imaging and enhancing tumor detection by integrating AI into MRI to propel demand
      • 7.4.1.4 Nuclear imaging
        • 7.4.1.4.1 Need for empowering AI-enhanced PET and SPECT imaging for precision oncology to drive growth
      • 7.4.1.5 X-ray Imaging
        • 7.4.1.5.1 Integrating AI-powered X-rays to automate detection of lung nodules to boost market
      • 7.4.1.6 Ultrasound
        • 7.4.1.6.1 Focus on integrating AI with ultrasound imaging to boost growth
      • 7.4.1.7 Other imaging modalities
    • 7.4.2 DIGITAL PATHOLOGY & HISTOPATHOLOGY
      • 7.4.2.1 Focus on examining tissue samples to diagnose diseases to boost market
    • 7.4.3 LIQUID BIOPSY & BIOMARKER DETECTION
      • 7.4.3.1 Advancements in non-invasive diagnostic technologies to propel growth
    • 7.4.4 GENETIC RISK PREDICTION
      • 7.4.4.1 Increased awareness of people regarding hereditary cancer risk to encourage growth
  • 7.5 TREATMENT PLANNING & PERSONALIZATION
    • 7.5.1 PERSONALIZED TREATMENT PLANNING
      • 7.5.1.1 Precision medicine & genomic analysis
        • 7.5.1.1.1 Need for adopting personalized therapies to improve treatment response to boost growth
      • 7.5.1.2 Radiomics & radiogenomics
        • 7.5.1.2.1 Emphasis on optimizing radiomics and radiogenomics for disease characterization to propel demand
      • 7.5.1.3 Predictive models for treatment response
        • 7.5.1.3.1 Adoption of predictive modeling to analyze genetic information to improve growth
      • 7.5.1.4 Treatment recommendation systems
        • 7.5.1.4.1 Need for enhancing treatment decisions with data-driven insights to propel growth
    • 7.5.2 RADIATION THERAPY
      • 7.5.2.1 Need for effective tumor targeting to boost growth
    • 7.5.3 CHEMOTHERAPY
      • 7.5.3.1 Focus on optimizing chemotherapy for targeted treatment and risk prediction to boost segmental growth
    • 7.5.4 IMMUNOTHERAPY
      • 7.5.4.1 Use of immunotherapy for personalized and effective cancer care to boost growth
    • 7.5.5 TARGETED THERAPY
      • 7.5.5.1 Combination & dose optimization
        • 7.5.5.1.1 Need for enhancing personalized dosing to augment segment growth
      • 7.5.5.2 AI-guided drug delivery
        • 7.5.5.2.1 Emphasis on achieving robust AI-powered drug delivery system to drive market
    • 7.5.6 SURGICAL PLANNING & ASSISTANCE
      • 7.5.6.1 Preoperative imaging & 3D modeling
        • 7.5.6.1.1 AI-driven 3D models for enhanced oncology care
      • 7.5.6.2 Intraoperative guidance and robotics
        • 7.5.6.2.1 Focus on integrating robotic surgery to enhance precision in treatment to drive market
      • 7.5.6.3 Postoperative analysis & recovery
        • 7.5.6.3.1 Emphasis on enhancing AI in postoperative care to drive demand
  • 7.6 PATIENT ENGAGEMENT & REMOTE MONITORING
    • 7.6.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
      • 7.6.1.1 Symptom management & virtual assistance tools are beneficial for chronic disease management
    • 7.6.2 REMOTE PATIENT MONITORING
      • 7.6.2.1 Need for AI-enhanced, real-time monitoring to augment growth
    • 7.6.3 PATIENT EDUCATION & EMPOWERMENT
      • 7.6.3.1 Improved health literacy and engagement with AI-curated insights
  • 7.7 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
    • 7.7.1 RECURRENCE MONITORING
      • 7.7.1.1 Need to improve cancer surveillance and accurate recurrence detection and prognosis to drive market
    • 7.7.2 LONG-TERM OUTCOME PREDICTION
      • 7.7.2.1 Need for personalized care plans and chronic side-effect management to augment market
    • 7.7.3 MENTAL HEALTH & SUPPORT SYSTEMS
      • 7.7.3.1 Prioritizing mental health support in cancer care to augment segmental growth
  • 7.8 DATA MANAGEMENT & ANALYTICS
    • 7.8.1 INTEGRATION OF GENOMIC AND CLINICAL DATA TO ACCELERATE DEMAND FOR AI-POWERED ANALYTICS
  • 7.9 OTHER APPLICATIONS

8 AI IN ONCOLOGY MARKET, BY CANCER TYPE

  • 8.1 INTRODUCTION
  • 8.2 SOLID TUMORS
    • 8.2.1 RISING PREVALENCE OF SOLID TUMORS TO BOOST NEED FOR AI-DRIVEN INNOVATIONS
    • 8.2.2 BREAST CANCER
    • 8.2.3 LUNG CANCER
    • 8.2.4 PROSTATE CANCER
    • 8.2.5 COLORECTAL CANCER
    • 8.2.6 BRAIN TUMOR
    • 8.2.7 OTHER SOLID TUMORS
  • 8.3 HEMATOLOGIC MALIGNANCIES
    • 8.3.1 RISING CASES OF BLOOD CANCER TO DRIVE MARKET
    • 8.3.2 LEUKEMIA
    • 8.3.3 LYMPHOMA
    • 8.3.4 MULTIPLE MYELOMA
    • 8.3.5 OTHER HEMATOLOGIC MALIGNANCIES
  • 8.4 OTHER CANCER TYPES

9 AI IN ONCOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HEALTHCARE PROVIDERS
    • 9.2.1 NEED FOR IMPROVED DIAGNOSTIC ACCURACY, PERSONALIZED TREATMENT PLANNING, AND ENHANCED WORKFLOW EFFICIENCY TO BOOST MARKET
    • 9.2.2 HOSPITALS & CLINICS
    • 9.2.3 SPECIALTY CENTERS
    • 9.2.4 LABORATORIES & DIAGNOSTIC CENTERS
    • 9.2.5 OTHER HEALTHCARE PROVIDERS
  • 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.3.1 NEED TO LEVERAGE AI FOR ACCELERATED ONCOLOGY DRUG DISCOVERY AND CLINICAL TRIALS TO BOOST GROWTH
  • 9.4 MEDICAL DEVICE/ EQUIPMENT COMPANIES
  • 9.5 ACADEMIC & RESEARCH INSTITUTIONS
  • 9.6 GOVERNMENT & REGULATORY AGENCIES
  • 9.7 HEALTHCARE PAYERS
  • 9.8 OTHER END USERS

10 AI IN ONCOLOGY MARKET, BY PLAYER TYPE

  • 10.1 INTRODUCTION
  • 10.2 NICHE/POINT SOLUTION PROVIDERS
    • 10.2.1 NICHE/POINT SOLUTION PROVIDERS ACCELERATE CANCER DRUG DISCOVERY AND DEVELOPMENT
  • 10.3 INTEGRATED SUITE/PLATFORM PROVIDERS
    • 10.3.1 INTEGRATED SUITE/PLATFORM PROVIDERS REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS
  • 10.4 TECHNOLOGY PROVIDERS
    • 10.4.1 DEMAND FOR IMPROVED ONCOLOGY WORKFLOWS TO DRIVE MARKET
  • 10.5 BUSINESS PROCESS SERVICE PROVIDERS
    • 10.5.1 FOCUS ON OPTIMIZING NON-CLINICAL ONCOLOGY WORKFLOWS TO PROPEL MARKET GROWTH

11 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL

  • 11.1 INTRODUCTION
  • 11.2 CLOUD-BASED MODEL
    • 11.2.1 NEED FOR ADVANCED CANCER RESEARCH AND TREATMENT TO BOOST USE OF CLOUD-BASED AI PLATFORMS
  • 11.3 ON-PREMISES MODEL
    • 11.3.1 NEED FOR ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISES MODEL
  • 11.4 HYBRID MODEL
    • 11.4.1 NEED FOR ENHANCING SCALABILITY AND DATA SECURITY IN DIAGNOSTICS TO DRIVE USE OF HYBRID-BASED AI PLATFORMS

12 AI IN ONCOLOGY MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Rising number of clinical trials and drug discovery to drive market
    • 12.2.3 CANADA
      • 12.2.3.1 Pharmaceutical giants advancing innovation and expanding access to clinical trials to fuel market
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Advanced healthcare system and collaborative efforts to boost market
    • 12.3.3 UK
      • 12.3.3.1 Government support for developing new AI platforms to drive innovation
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing R&D pipeline for oncology trials to drive market
    • 12.3.5 ITALY
      • 12.3.5.1 Favorable regulatory scenarios to propel AI adoption in oncology
    • 12.3.6 SPAIN
      • 12.3.6.1 Established network of research centers to propel market
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Increasing healthcare expenditure to drive demand for oncology solutions
    • 12.4.3 INDIA
      • 12.4.3.1 Growing cancer burden and healthcare disparities to fuel adoption of AI in oncology
    • 12.4.4 JAPAN
      • 12.4.4.1 Aging population and rising cancer rates to drive growth
    • 12.4.5 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Rising cases of breast cancer to support market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Use of AI in pediatric cancer treatment and chemotherapy complications to fuel market growth
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Growing cancer cases and increasing clinical trials to drive growth
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE ANALYSIS OF KEY PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.8 BRAND/SOFTWARE COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS
    • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 NVIDIA CORPORATION
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 GE HEALTHCARE
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches & approvals
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 SIEMENS HEALTHINEERS AG
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Solutions offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches & approvals
        • 14.1.3.3.2 Deals
        • 14.1.3.3.3 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Right to win
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 F. HOFFMANN-LA ROCHE LTD
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches & approvals
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Right to win
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 INSILICO MEDICINE
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Solutions offered
      • 14.1.5.3 Recent developments
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Right to win
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 CONCERTAI
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches & approvals
        • 14.1.6.3.2 Deals
    • 14.1.7 MEDTRONIC
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Product launches & approvals
        • 14.1.7.3.2 Deals
    • 14.1.8 ORACLE
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches & approvals
        • 14.1.8.3.2 Deals
    • 14.1.9 KONINKLIJKE PHILIPS N.V.
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Solutions offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
    • 14.1.10 PREDICTIVE ONCOLOGY
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Solutions offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches & approvals
        • 14.1.10.3.2 Deals
    • 14.1.11 EXSCIENTIA
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Solutions offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Product launches & approvals
        • 14.1.11.3.2 Deals
        • 14.1.11.3.3 Expansions
        • 14.1.11.3.4 Other developments
    • 14.1.12 PATHAI, INC.
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Solutions offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Product launches & approvals
        • 14.1.12.3.2 Deals
    • 14.1.13 CUREMETRIX, INC.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Solutions offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Other developments
    • 14.1.14 MINDPEAK GMBH
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Solutions offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Product launches & approvals
        • 14.1.14.3.2 Deals
        • 14.1.14.3.3 Other developments
    • 14.1.15 PAIGE AI, INC.
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Solutions offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Product launches & approvals
        • 14.1.15.3.2 Deals
        • 14.1.15.3.3 Other developments
    • 14.1.16 TEMPUS AI, INC.
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products/Solutions offered
      • 14.1.16.3 Recent developments
        • 14.1.16.3.1 Product launches & approvals
        • 14.1.16.3.2 Deals
        • 14.1.16.3.3 Expansions
        • 14.1.16.3.4 Other developments
    • 14.1.17 IKTOS
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products/Solutions offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Deals
        • 14.1.17.3.2 Other developments
  • 14.2 OTHER PLAYERS
    • 14.2.1 AZRA AI
    • 14.2.2 CUREMATCH, INC.
    • 14.2.3 ONCOLENS
    • 14.2.4 TRIOMICS
    • 14.2.5 CLINAKOS
    • 14.2.6 PERTHERA, INC.
    • 14.2.7 CELLWORKS GROUP, INC.
    • 14.2.8 BIOMY, INC.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 USD EXCHANGE RATES, 2021-2023
  • TABLE 2 FACTOR ANALYSIS
  • TABLE 3 AI IN ONCOLOGY MARKET: RISK ASSESSMENT
  • TABLE 4 AI IN ONCOLOGY MARKET: IMPACT ANALYSIS
  • TABLE 5 AI IN ONCOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 6 IMPACT OF PORTER'S FIVE FORCES ON AI IN ONCOLOGY MARKET
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 JURISDICTION ANALYSIS OF TOP PATENT APPLICANT COUNTRIES FOR AI IN ONCOLOGY
  • TABLE 13 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023 (USD THOUSAND)
  • TABLE 14 AI IN ONCOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025
  • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS (%)
  • TABLE 16 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 17 UNMET NEEDS IN AI IN ONCOLOGY MARKET
  • TABLE 18 END USER EXPECTATIONS IN AI IN ONCOLOGY MARKET
  • TABLE 19 AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 20 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 21 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 22 AI IN ONCOLOGY MARKET FOR DEEP LEARNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 23 AI IN ONCOLOGY MARKET FOR SUPERVISED LEARNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 24 AI IN ONCOLOGY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 25 AI IN ONCOLOGY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 26 AI IN ONCOLOGY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 27 AI IN ONCOLOGY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 28 AI IN ONCOLOGY MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 29 AI IN ONCOLOGY MARKET FOR COMPUTER VISION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 30 AI IN ONCOLOGY MARKET FOR IMAGE ANALYSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 31 AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 32 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 33 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 34 AI IN ONCOLOGY MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 35 AI IN ONCOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 36 AI IN ONCOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 37 AI IN ONCOLOGY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 38 AI IN ONCOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 39 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 40 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 41 AI IN ONCOLOGY MARKET FOR PRECLINICAL TESTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 42 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELING FOR HUMAN TRIALS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 43 AI IN ONCOLOGY MARKET FOR CLINICAL TRIAL OPTIMIZATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 44 AI IN ONCOLOGY MARKET FOR ADAPTIVE TRIAL DESIGN & MONITORING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 45 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 46 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 47 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 48 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 49 AI IN ONCOLOGY MARKET FOR MAMMOGRAPHY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 50 AI IN ONCOLOGY MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 51 AI IN ONCOLOGY MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2022-2030 (USD MILLION)
  • TABLE 52 AI IN ONCOLOGY MARKET FOR NUCLEAR IMAGING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 53 AI IN ONCOLOGY MARKET FOR X-RAY IMAGING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 54 AI IN ONCOLOGY MARKET FOR ULTRASOUND, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 55 AI IN ONCOLOGY MARKET FOR OTHER IMAGING MODALITIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 56 AI IN ONCOLOGY MARKET FOR DIGITAL PATHOLOGY & HISTOPATHOLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 57 AI IN ONCOLOGY MARKET FOR LIQUID BIOPSY & BIOMARKER DETECTION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 58 AI IN ONCOLOGY MARKET FOR GENETIC RISK PREDICTION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 59 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 60 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 61 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 62 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 63 AI IN ONCOLOGY MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 64 AI IN ONCOLOGY MARKET FOR RADIOMICS & RADIOGENOMICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 65 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 66 AI IN ONCOLOGY MARKET FOR TREATMENT RECOMMENDATION SYSTEMS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 67 AI IN ONCOLOGY MARKET FOR RADIATION THERAPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 68 AI IN ONCOLOGY MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 69 AI IN ONCOLOGY MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 70 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 71 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 72 AI IN ONCOLOGY MARKET FOR COMBINATION & DOSE OPTIMIZATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 73 AI IN ONCOLOGY MARKET FOR AI-GUIDED DRUG DELIVERY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 74 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 75 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 76 AI IN ONCOLOGY MARKET FOR PREOPERATIVE IMAGING & 3D MODELING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 77 AI IN ONCOLOGY MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 78 AI IN ONCOLOGY MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 79 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 80 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 81 AI IN ONCOLOGY MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 82 AI IN ONCOLOGY MARKET FOR REMOTE PATIENT MONITORING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 83 AI IN ONCOLOGY MARKET FOR PATIENT EDUCATION & EMPOWERMENT, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 84 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 85 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 86 AI IN ONCOLOGY MARKET FOR RECURRENCE MONITORING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 87 AI IN ONCOLOGY MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 88 AI IN ONCOLOGY MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 89 AI IN ONCOLOGY MARKET FOR DATA MANAGEMENT & ANALYTICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 90 AI IN ONCOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 91 AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 92 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 93 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 94 AI IN ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 95 AI IN ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 96 AI IN ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 97 AI IN ONCOLOGY MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 98 AI IN ONCOLOGY MARKET FOR BRAIN TUMORS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 99 AI IN ONCOLOGY MARKET FOR OTHER SOLID TUMORS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 100 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 101 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 102 AI IN ONCOLOGY MARKET FOR LEUKEMIA, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 103 AI IN ONCOLOGY MARKET FOR LYMPHOMA, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 104 AI IN ONCOLOGY MARKET FOR MULTIPLE MYELOMA, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 105 AI IN ONCOLOGY MARKET FOR OTHER HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 106 AI IN ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 107 AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 108 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 109 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 110 AI IN ONCOLOGY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 111 AI IN ONCOLOGY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 112 AI IN ONCOLOGY MARKET FOR LABORATORIES & DIAGNOSTIC CENTERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 113 AI IN ONCOLOGY MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 114 AI IN ONCOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 115 AI IN ONCOLOGY MARKET FOR MEDICAL DEVICE/ EQUIPMENT COMPANIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 116 AI IN ONCOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 117 AI IN ONCOLOGY MARKET FOR GOVERNMENT & REGULATORY AGENCIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 118 AI IN ONCOLOGY MARKET FOR HEALTHCARE PAYERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 119 AI IN ONCOLOGY MARKET FOR OTHER END USERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 120 AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 121 AI IN ONCOLOGY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 122 AI IN ONCOLOGY MARKET FOR INTEGRATED SUITE/PLATFORM PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 123 AI IN ONCOLOGY MARKET FOR TECHNOLOGY PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 124 AI IN ONCOLOGY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 125 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 126 AI IN ONCOLOGY MARKET FOR CLOUD-BASED MODEL, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 127 AI IN ONCOLOGY MARKET FOR ON-PREMISES MODEL, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 128 AI IN ONCOLOGY MARKET FOR HYBRID MODEL, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 129 AI IN ONCOLOGY MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 132 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 133 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 138 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 145 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 150 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 151 US: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 152 US: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 153 US: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 154 US: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 155 US: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 156 US: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 157 US: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 158 US: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 159 US: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 160 US: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 161 US: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 162 US: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 163 US: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 164 US: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 165 US: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 166 US: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 167 US: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 168 US: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 169 US: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 170 US: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 171 CANADA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 172 CANADA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 173 CANADA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 174 CANADA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 175 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 176 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 177 CANADA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 178 CANADA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 179 CANADA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 180 CANADA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 181 CANADA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 182 CANADA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 CANADA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 184 CANADA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 185 CANADA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 186 CANADA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 187 CANADA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 188 CANADA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 189 CANADA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 190 CANADA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 191 EUROPE: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 192 EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 193 EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 194 EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 195 EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 196 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 197 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 198 EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 199 EUROPE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 200 EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 201 EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 202 EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 203 EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 204 EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 205 EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 206 EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 207 EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 208 EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 209 EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 210 EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 211 EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 212 GERMANY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 213 GERMANY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 214 GERMANY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 215 GERMANY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 216 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 217 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 218 GERMANY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 219 GERMANY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 220 GERMANY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 221 GERMANY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 222 GERMANY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 223 GERMANY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 224 GERMANY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 225 GERMANY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 226 GERMANY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 227 GERMANY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 228 GERMANY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 229 GERMANY: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 230 GERMANY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 231 GERMANY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 232 UK: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 233 UK: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 234 UK: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 235 UK: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 236 UK: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 237 UK: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 238 UK: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 239 UK: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 240 UK: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 241 UK: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 242 UK: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 243 UK: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 244 UK: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 245 UK: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 246 UK: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 247 UK: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 248 UK: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 249 UK: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 250 UK: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 251 UK: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 252 FRANCE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 253 FRANCE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 254 FRANCE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 255 FRANCE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 256 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 257 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 258 FRANCE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 259 FRANCE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 260 FRANCE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 261 FRANCE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 262 FRANCE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 263 FRANCE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 264 FRANCE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 265 FRANCE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 266 FRANCE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 267 FRANCE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 268 FRANCE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 269 FRANCE: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 270 FRANCE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 271 FRANCE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 272 ITALY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 273 ITALY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 274 ITALY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 275 ITALY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 276 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 277 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 278 ITALY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 279 ITALY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 280 ITALY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 281 ITALY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 282 ITALY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 283 ITALY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 284 ITALY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 285 ITALY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 286 ITALY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 287 ITALY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 288 ITALY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 289 ITALY: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 290 ITALY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 291 ITALY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 292 SPAIN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 293 SPAIN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 294 SPAIN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 295 SPAIN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 296 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 297 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 298 SPAIN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 299 SPAIN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 300 SPAIN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 301 SPAIN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 302 SPAIN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 303 SPAIN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 304 SPAIN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 305 SPAIN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 306 SPAIN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 307 SPAIN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 308 SPAIN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 309 SPAIN: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 310 SPAIN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 311 SPAIN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 312 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 313 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 314 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 315 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 316 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 317 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 318 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 319 REST OF EUROPE AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 320 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 321 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 322 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 323 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 324 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 325 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 326 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 327 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 328 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 329 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 330 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 331 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 332 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 335 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 336 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 337 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 338 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 340 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 341 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 343 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 344 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 346 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 347 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 348 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 349 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 353 CHINA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 354 CHINA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 355 CHINA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 356 CHINA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 357 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 358 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 359 CHINA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 360 CHINA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 361 CHINA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 362 CHINA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 363 CHINA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 364 CHINA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 365 CHINA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 366 CHINA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 367 CHINA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 368 CHINA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 369 CHINA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 370 CHINA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 371 CHINA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 372 CHINA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 373 INDIA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 374 INDIA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 375 INDIA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 376 INDIA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 377 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 378 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 379 INDIA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 380 INDIA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 381 INDIA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 382 INDIA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 383 INDIA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 384 INDIA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 385 INDIA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 386 INDIA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 387 INDIA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 388 INDIA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 389 INDIA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 390 INDIA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 391 INDIA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 392 INDIA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 393 JAPAN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 394 JAPAN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 395 JAPAN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 396 JAPAN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 397 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 398 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 399 JAPAN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 400 JAPAN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)S
  • TABLE 401 JAPAN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 402 JAPAN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 403 JAPAN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 404 JAPAN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 405 JAPAN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 406 JAPAN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 407 JAPAN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 408 JAPAN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 409 JAPAN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 410 JAPAN: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 411 JAPAN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 412 JAPAN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 413 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 414 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 415 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 416 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 417 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 418 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 419 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 420 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 421 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 422 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 423 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 424 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 425 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 426 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 427 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 428 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 429 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 430 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 431 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 432 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 433 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 434 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 435 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 436 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 437 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 438 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 439 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 440 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 441 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 442 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 443 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 444 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 445 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 446 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 447 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 448 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 449 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 450 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 451 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 452 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 453 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 454 BRAZIL: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 455 BRAZIL: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 456 BRAZIL: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 457 BRAZIL: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 458 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 459 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 460 BRAZIL: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 461 BRAZIL: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 462 BRAZIL: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 463 BRAZIL: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 464 BRAZIL: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 465 BRAZIL: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 466 BRAZIL: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 467 BRAZIL: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 468 BRAZIL: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 469 BRAZIL: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 470 BRAZIL: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 471 BRAZIL: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 472 BRAZIL: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 473 BRAZIL: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 474 MEXICO: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 475 MEXICO: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 476 MEXICO: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 477 MEXICO: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 478 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 479 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 480 MEXICO: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 481 MEXICO: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 482 MEXICO: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 483 MEXICO: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 484 MEXICO: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 485 MEXICO: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 486 MEXICO: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 487 MEXICO: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 488 MEXICO: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 489 MEXICO: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 490 MEXICO: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 491 MEXICO: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 492 MEXICO: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 493 MEXICO: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 494 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 495 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 496 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 497 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 498 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 499 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 500 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 501 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 502 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 503 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 504 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 505 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 506 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 507 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 508 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 509 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 510 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 511 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 512 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 513 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 514 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 515 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 516 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 517 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 518 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 519 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 520 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 521 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 522 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 523 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 524 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 525 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 526 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 527 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 528 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 529 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 530 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 531 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 532 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 533 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 534 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 535 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 536 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 537 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 538 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 539 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 540 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 541 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 542 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 543 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 544 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 545 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 546 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 547 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 548 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 549 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 550 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 551 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 552 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 553 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 554 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 555 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022-2030 (USD MILLION)
  • TABLE 556 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 557 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 558 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 559 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 560 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 561 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 562 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 563 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 564 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 565 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 566 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 567 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 568 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 569 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022-2030 (USD MILLION)
  • TABLE 570 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 571 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 572 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 573 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 574 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022-2030 (USD MILLION)
  • TABLE 575 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • TABLE 576 AI IN ONCOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 577 AI IN ONCOLOGY MARKET: PLAYER TYPE FOOTPRINT
  • TABLE 578 AI IN ONCOLOGY MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 579 AI IN ONCOLOGY MARKET: DEPLOYMENT MODEL FOOTPRINT
  • TABLE 580 AI IN ONCOLOGY MARKET: REGION FOOTPRINT
  • TABLE 581 AI IN ONCOLOGY MARKET: LIST OF KEY STARTUPS/SMES
  • TABLE 582 AI IN ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 583 AI IN ONCOLOGY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 584 AI IN ONCOLOGY MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 585 AI IN ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 586 AI IN ONCOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021- NOVEMBER 2024
  • TABLE 587 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 588 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 589 NVIDIA CORPORATION: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 590 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 591 GE HEALTHCARE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 592 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 593 GE HEALTHCARE: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 594 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 595 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 596 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 597 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 598 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 599 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 600 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 601 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 602 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 603 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 604 INSILICO MEDICINE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 605 INSILICO MEDICINE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 606 INSILICO MEDICINE: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 607 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 608 CONCERTAI: COMPANY OVERVIEW
  • TABLE 609 CONCERTAI: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 610 CONCERTAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 611 CONCERTAI: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 612 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 613 MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 614 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 615 MEDTRONIC: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 616 ORACLE: COMPANY OVERVIEW
  • TABLE 617 ORACLE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 618 ORACLE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 619 ORACLE: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 620 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 621 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 622 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 623 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 624 PREDICTIVE ONCOLOGY: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 625 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 626 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 627 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 628 EXSCIENTIA: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 629 EXSCIENTIA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 630 EXSCIENTIA: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 631 EXSCIENTIA: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 632 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 633 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 634 PATHAI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 635 PATHAI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 636 PATHAI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 637 CUREMETRIX, INC.: COMPANY OVERVIEW
  • TABLE 638 CUREMETRIX, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 639 CUREMETRIX, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 640 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 641 MINDPEAK GMBH: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 642 MINDPEAK GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 643 MINDPEAK GMBH: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 644 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 645 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 646 PAIGE AI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 647 PAIGE AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 648 PAIGE AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 649 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 650 TEMPUS AI, INC.: COMPANY OVERVIEW
  • TABLE 651 TEMPUS AI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 652 TEMPUS AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 653 TEMPUS AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 654 TEMPUS AI, INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 655 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 656 IKTOS: COMPANY OVERVIEW
  • TABLE 657 IKTOS: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 658 IKTOS: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 659 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024

List of Figures

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION
  • FIGURE 5 AI IN ONCOLOGY MARKET: REVENUE ESTIMATION APPROACH
  • FIGURE 6 BOTTOM-UP APPROACH (2A): END USER SPENDING ON AI IN ONCOLOGY
  • FIGURE 7 BOTTOM-UP APPROACH (2B): END USER SPENDING ON AI IN ONCOLOGY
  • FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2030)
  • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 INTEGRATED SUITE/PLATFORM PROVIDERS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 13 DIAGNOSIS & EARLY DETECTION SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030
  • FIGURE 14 SOLID TUMORS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 15 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2030 (USD MILLION)
  • FIGURE 16 MACHINE LEARNING SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030
  • FIGURE 17 HEALTHCARE PROVIDERS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 18 ASIA PACIFIC TO ACHIEVE HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 19 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
  • FIGURE 20 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 21 CLOUD-BASED MODEL AND US ACCOUNTED FOR SIGNIFICANT SHARE IN 2023
  • FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 23 GROWTH RATES OF EMERGING MARKETS TO BE HIGHER THAN THOSE OF DEVELOPED MARKETS DURING FORECAST PERIOD
  • FIGURE 24 AI IN ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 NEW CANCER CASES AND CANCER DEATHS IN US, 2024
  • FIGURE 26 FUNDING RECEIVED BY AI IN ONCOLOGY COMPANIES IN 2024
  • FIGURE 27 NUMBER OF CANCER PUBLICATIONS OVER TIME (WITH OR WITHOUT AI AND RADIOMICS)
  • FIGURE 28 DISTRIBUTION OF CANCER CLINICAL TRIALS, BY PHASE
  • FIGURE 29 AI IN ONCOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 AI IN ONCOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 31 PORTER'S FIVE FORCES ANALYSIS OF AI IN ONCOLOGY MARKET
  • FIGURE 32 PATENT PUBLICATION TRENDS IN AI IN ONCOLOGY MARKET, 2015-2024
  • FIGURE 33 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR "AI IN ONCOLOGY" PATENTS (JANUARY 2015-SEPTEMBER 2024)
  • FIGURE 34 MAJOR PATENTS IN AI IN ONCOLOGY MARKET (JANUARY 2015- SEPTEMBER 2024)
  • FIGURE 35 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS
  • FIGURE 37 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 38 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 39 INVESTMENT AND FUNDING SCENARIO IN AI IN ONCOLOGY MARKET
  • FIGURE 40 POTENTIAL OF GENERATIVE AI IN AI IN ONCOLOGY MARKET
  • FIGURE 41 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 42 NEW CANCER CASES IN US, BY CANCER TYPE, 2024
  • FIGURE 43 PERCENTAGE ESTIMATION OF HEMATOLOGIC MALIGNANCY CASES IN US, BY TYPE, 2024
  • FIGURE 44 AI IN ONCOLOGY MARKET, BY REGION, 2023 (USD MILLION)
  • FIGURE 45 NORTH AMERICA: AI IN ONCOLOGY MARKET SNAPSHOT
  • FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION, 2021 VS. 2022
  • FIGURE 47 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (MALES)
  • FIGURE 48 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (FEMALES)
  • FIGURE 49 INCIDENCE OF CANCER IN MALES IN ITALY, BY CANCER TYPE, 2022
  • FIGURE 50 INCIDENCE OF CANCER IN FEMALES IN ITALY, BY CANCER TYPE, 2022
  • FIGURE 51 ASIA PACIFIC: AI IN ONCOLOGY MARKET SNAPSHOT
  • FIGURE 52 REVENUE ANALYSIS OF TOP 5 PLAYERS, 2019-2023 (USD BILLION)
  • FIGURE 53 AI IN ONCOLOGY MARKET SHARE ANALYSIS, 2023
  • FIGURE 54 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 55 AI IN ONCOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 56 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 57 COMPANY VALUATION OF KEY PLAYERS, 2024
  • FIGURE 58 EV/EBITDA OF KEY PLAYERS, 2024
  • FIGURE 59 AI IN ONCOLOGY MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 60 NVIDIA CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 61 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
  • FIGURE 62 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 63 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 64 MEDTRONIC: COMPANY SNAPSHOT (2023)
  • FIGURE 65 ORACLE: COMPANY SNAPSHOT (2023)
  • FIGURE 66 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)
  • FIGURE 68 EXSCIENTIA: COMPANY SNAPSHOT